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Abstract
Condensed O,N-heterocycles containing tetrahydro-1,4-benzoxazepine and tetrahydroquinoline moieties were prepared by a
regio- and diastereoselective domino Knoevenagel–[1,5]-hydride shift cyclization reaction of a 4-aryl-2-phenyl-1,4-benzoxazepine
derivative obtained from flavanone. The relative configuration of products were determined by the correlation of 3JH,H coupling
data with the geometry of major conformers accessed by DFT conformational analysis. Separated enantiomers of the products were
characterized by HPLC-ECD data, which allowed their configurational assignment on the basis of TDDFT-ECD calculation of the
solution conformers. Two compounds showed neuroprotective activities against hydrogen peroxide (H2O2) or β-amyloid25–35
(Aβ25–35)-induced cellular injuries in human neuroblastoma SH-SY5Y cells in the range of those of positive controls.
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Scheme 1: Domino Knoevenagel–[1,5]-hydride shift cyclization reaction for the preparation of condensed 1,4-benzoxazepines.
Introduction
The 1,4-benzoxazepine structural unit and its analogues are
found in several pharmacologically active derivatives such as
the selective 5-HT1A agonist SUN 8399 (1) [1], the neuropro-
tective piclozotan (2) [2,3], the antihistaminic rocastine (3)
[4,5], and the antihelmintic 4 [6] (Figure 1).
Figure 1: Pharmacologically active derivatives 1–4 containing the 1,4-
benzoxazepine moiety or its analogue.
We report herein the preparation of two neuroprotective
condensed 2-phenyl-1,4-benzoxazepines rac-7a,b through the
diastereoselective domino Knoevenagel–1,5-hydride
shift cyclization reaction rac-5→rac-7a,b from the readily
available 4-aryl-2-phenyl-1,4-benzoxazepine derivative, rac-5
(Scheme 1).
Ring-closure transformations involving C(sp3)–H bond func-
tionalization in an internal redox process, particularly involving
C–H bonds in α-position to a tertiary amine nitrogen atom, has
attracted considerable attention due to its synthetic potential
[7-11]. The intramolecular “tert-amino effect” induced cycliza-
tion consists in (1) the cleavage of the C(sp3)–H bond α to a
tertiary amine nitrogen through [1,5]-hydride shift (rac-6→A)
(Scheme 1) to afford the zwitterionic intermediate A and (2)
subsequent 6-endo cyclization (A→rac-7a,b).
The stereoselective version of “tert-amino effect” induced
cyclization using chiral metal-catalyzed [12-15] or organo-
catalytic [16,17] reactions and the mechanism of the stereospe-
cific hydride transfer have been recently studied by several
research groups. The synthetic potential of the diastereoselec-
tive domino Knoevenagel–[1,5]-hydride shift cyclization reac-
tion was exploited in our present work for the preparation of
condensed O,N-heterocycles with the 1,2,8,9-tetrahydro-7bH-
quinolino[1,2-d][1,4]benzoxazepine skeleton, the neuroprotec-
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Scheme 2: i) a) NaN3, CF3COOH, b) H2O, Δ (77%); ii) LiAlH4, dry THF, Δ (80%); iii) 11b, K2CO3, toluene, Δ (71%); iv) 12, MgSO4, CHCl3 (96%);
v) 13, MgSO4, CHCl3 (22%); vi) 14, MgSO4, CHCl3 (81%).
tive activities of which were tested against hydrogen peroxide
(H2O2), Alzheimer's amyloid β-peptide fragment Aβ25–35 and
oxygen–glucose deprivation (OGD)-induced neurotoxicity in
human neuroblastoma SH-SY5Y cells.
Results and Discussion
The starting material 4-aryl-2-phenyl-1,4-benzoxazepine (rac-
5) for the domino Knoevenagel–[1,5]-hydride shift cyclization
reaction was prepared from rac-flavanone (rac-8) in four steps
(Scheme 2).
The Schmidt reaction of rac-8 was carried out according to the
procedure of Litkey and Patonay [18] affording the racemic 3,4-
dihydro-2-phenyl-1,4-benzoxazepine-5-one (rac-9) with high
regioselectivity, which was reduced to (rac)-10 with LAH in
dry THF. In the following step, the N-arylation of rac-10 was
performed through a nucleophilic aromatic substitution by using
2-fluoro-5-nitrobenzaldehyde (11b) to give rac-5 containing a
tertiary arylamine nitrogen in 71% yield. With the 2-chloro-5-
nitrobenzaldehyde reagent, only 3% yield for rac-5 could be
achieved. Subsequently rac-5 was reacted with 1,3-dimethyl-
barbituric acid (12), Meldrum’s acid (13) and malononitrile (14)
all containing active methylene groups, which initiated a
domino reaction (Scheme 2). The Knoevenagel reaction of the
formyl group in rac-5 and the active methylene groups of 12–14
afforded the intermediates rac-6a–c (Scheme 1), which under-
went regioselective [1,5]-hydride shift with participation of the
benzylic hydrogen to result in the zwitterionic iminium ion
intermediates A. The 6-endo cyclization of this intermediate
gave rac-trans-7a,b with high diastereoselectivity, which was
governed by the C-2 chirality center of intermediate A. In
contrast to the domino reaction with 1,3-dimethylbarbituric acid
(12) and Meldrum’s acid (13), the reaction with malonitrile (14)
stopped at the stage of the Knoevenagel product rac-7c with
MgSO4 in CHCl3 and further cyclization did not occur when
heated in DMSO at 150 °C or refluxed in n-butanol.
The NMR data of 7a,b clearly indicated that they were single
diastereomers and the determination of the relative configur-
ation was carried out by the correlation of NMR data and DFT
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conformational analysis of cis- and trans-7a,b (Figure 2 and
Figure 3).
Figure 2: Lowest-energy conformers of a) trans-(2S,15aS)-7a
(>99.9%) with the replacement of the N-methyl groups by hydrogen
atoms; b) trans-(2S,15aS)-7b (97.9%) obtained by the B3LYP/6-
31G(d) reoptimization of the initial MMFF conformers. Boltzmann
weights for the same conformers in the PCM calculations are 99.8%
and 95.8%, respectively.
Figure 3: Lowest-energy conformers of a) cis-(2R,15aS)-7a (99.4%)
with the replacement of the N-methyl groups by hydrogen atoms;
b) cis-(2R,15aS)-7b (84.5%) obtained by the B3LYP/6-31G(d) reopti-
mization of the initial MMFF conformers. Boltzmann weights for the
same conformers in the PCM calculations are 97.7% and 82.5%, res-
pectively.
Although the hydrogens 2-H and 15a-H of cis-7a,b are expected
to point toward the same side of the molecules, the analysis of
the computed solution conformers of cis-7a,b revealed that the
orientation and distance (>4.6 Å) of these methine protons
(Figure 3) does not allow for the detection of their NOE contact,
rendering the NOE-based assignment of the relative configur-
ation ambiguous. Similarly, no NOE correlation is expected
between 2-H and 15a-H of trans-7a,b, which was also evident
from the structures of their computed lowest-energy conformers
(Figure 2). Accordingly, no characteristic NOE was observed
between these methine protons for 7a,b, which did not help for
the assignment of the relative configuration. However, in the
computed solution conformers of cis-7a,b, the oxazepine ring
adopts a twist boat conformation with axial 2-H showing
gauche  orientation with adjacent 3-H protons (e.g.,
ω2-Hax,C-2,C-3,3-Hax ≈ 36.2°, ω2-Hax,C-2,C-3,3-Heq ≈ −79.2° in 7a),
suggesting small 3J2-H,3-H couplings.
Whereas in the computed solution conformers of trans-7a,b
(Figure 2), the oxazepine ring adopts a boat conformation
showing a trans-diaxial relationship with the adjacent 3-Hax.
In accordance with the calculations, the measured values
of the 3J2-Hax,3-H (11.5 and 3.2 Hz) corroborate that the
couplings between 2-Hax and 3-Hs derive from trans-diaxial
(ω2-Hax,C-2,C-3,3-Hax ≈ 180°) and gauche (ω2-Hax,C-2,C-3,3-Heq ≈
60°) orientations, which is only feasible with the trans relative
configuration of 7a,b. Thus in the course of the cyclization, the
attack of the carbanion to the iminium carbon of intermediate A
occurred with trans-diastereoselectivity to the C-2 phenyl
group. The formation of the diastereomeric cis-7a,b could not
be detected.
The chiral HPLC analysis of the products 7a,b also confirmed
that the reaction took place diastereoselectively and enan-
tiomers of trans-7a,b were separated on a Chiralpak IA column
using hexane/dichloromethane as eluent and online HPLC-ECD
spectra of the separated enantiomers were recorded. Due to their
similar chromophoric system, the HPLC-ECD spectra of 7a and
7b were quite similar. The first-eluting enantiomer of 7a had an
intense broad positive Cotton effect (CE) at 378 nm, negative
ones at 314, 305, 272 nm and positive ones at 284, 279 and
224 nm (Figure 4a).
The HPLC-ECD spectrum of the first-eluting enantiomer of 7b
showed similar ECD pattern with somewhat different shape and
intensities in the 290–240 nm range (Figure 4b). TDDFT-ECD
calculation was proved an efficient method to determine the
absolute configuration of separated stereoisomers of bioactive
synthetic [19] and natural derivatives [20,21] on the basis of
their HPLC-ECD spectra.
For the configurational assignment of the separated enan-
tiomers, TDDFT-ECD calculations were carried out on the
solution conformers of (2S,15aS)-7d (N-methyl groups were
replaced by hydrogens for the calculation) and (2S,15aS)-7b
and computed ECD curves were compared with the measured
HPLC-ECD ones of the separated enantiomers of trans-7a,b
(Figure 4a and Figure 4b). The computed TDDFT-ECD spectra
of (2S,15aS)-7d and (2S,15aS)-7b gave good agreement with
the experimental HPLC-ECD spectra of the second-eluting
enantiomers (Figure 4a,b), which allowed determining the
absolute configuration of their second-eluting enantiomers
(negative CEs at 370 and 371 nm, respectively) as (2S,15aS).
The good agreement between the experimental HPLC-ECD and
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Figure 4: HPLC-ECD spectra of the first-eluting (black curve) and second-eluting (red curve) enantiomers of a) trans-7a, and b) trans-7b compared
with the computed ECD spectra of the gas-phase optimized conformers (>1%) of model compound (2S,15aS)-7d (1 conformer, B3LYP/TZVP) and
(2S,15aS)-7b (2 conformers, BH&HLYP/TZVP). Bars represent the computed rotational strength values (R/8) of the lowest-energy conformer.
c) Structure of the (2S,15aS)-7d model compound of trans-7a used for the conformational analysis and ECD calculations.
computed ECD spectra of 7a,b not only allowed the configura-
tional assignment of their separated enantiomers but also
confirmed independently the trans-diastereoselectivity of the
cyclization.
The neuroprotective activities of rac-7a,b and rac-5 were tested
against hydrogen peroxide (H2O2), β-amyloid-25-35 (Aβ25–35)
and oxygen–glucose deprivation (OGD)-induced neurotoxicity
in human neuroblastoma SH-SY5Y cells [22]. The preliminary
screenings showed that rac-7a at 10 µM concentration
displayed neuroprotective activity against H2O2-induced
cellular injuries in human neuroblastoma SH-SY5Y cells with
16.4% increase in cell viability (Figure 5), while 10 µM of rac-
7b increased cell viability in Aβ25–35-induced neurotoxicity by
22.8% (Figure 6).
The positive controls with N-L-acetylcysteine (NAC) [23] and
epigallocatechin gallate (EGCG) [24] increased cell viability by
17.3% and 22.4% in H2O2 and Aβ25–35 model, respectively.
Compounds rac-7a,b and rac-5 did not show acetylcholin-
esterase inhibitory effect.
Figure 5: Protective effect of compound 7a on hydrogen peroxide-
induced neurotoxicity in SH-SY5Y cells. ##P < 0.01 vs control group,
**P< 0.01 vs hydrogen peroxide group.
Conclusion
Regioselective domino Knoevenagel–[1,5]-hydride shift
cyclization reactions of a 4-aryl-2-phenyl-1,4-benzoxazepine
Beilstein J. Org. Chem. 2014, 10, 2594–2602.
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Figure 6: Protective effect of compound 7b on β-amyloid25–35-induced
neurotoxicity in SH-SY5Y cells. ##P < 0.01 vs control group, **P< 0.01
vs β-amyloid25–35 group.
derivative afforded three condensed O,N-heterocycles
containing tetrahydro-1,4-benzoxazepine and tetrahydroquino-
line moieties. trans-Diastereoselectivity of the cyclizations was
determined by the correlation of 3JH,H coupling constants with
the geometry of the computed conformers, while (2R,15aR)
absolute configurations of 7a,b were assigned to the separated
enantiomers showing positive CE for the lowest-energy ECD
transition by the comparison of the experimental HPLC-ECD
spectra with those obtained by the TDDFT-ECD calculations of
the solution conformers. Compound 7a showed neuroprotective
activity against hydrogen peroxide (H2O2), while 7b against
β-amyloid25–35 (Aβ25–35)-induced cellular injuries in human
neuroblastoma SH-SY5Y cells with 16.4% and 22.8% increase
in cell viability at 10 μM concentrations, respectively.
Experimental
Melting points were determined on a Kofler hot-stage appa-
ratus and are uncorrected. The NMR spectra were recorded on
Bruker-AMX 500 (1H: 500 MHz; 13C: 125 MHz) and Bruker
Avance II 400 (1H: 400 MHz; 13C: 100 MHz) spectrometers
using TMS as internal standard. Chemical shifts were reported
as δ in ppm and 3JH,H coupling constants in Hz. Chiral HPLC
separation of 7a,b were performed on a Jasco HPLC system
with Chiralpak IA column (5 μm, 150 × 4.6 mm, hexane/
dichloromethane 80:20 or 70:30 eluents, 1 mL min−1 flow rate)
and HPLC-ECD spectra were recorded in stopped-flow mode
on a JASCO J-810 electronic circular dichroism spectropo-
larimeter equipped with a 10 mm HPLC flow cell. ECD ellip-
ticity (Φ) values were not corrected for concentration. For an
HPLC-ECD spectrum, three consecutive scans were recorded
and averaged with 2 nm bandwidth, 1 s response, and standard
sensitivity. The HPLC-ECD spectrum of the eluent recorded in
the same way was used as background. The concentration of the
injected sample was set so that the HT value did not exceed
500 V in the HT channel down to 230 nm. IR spectra were
recorded on a JASCO FTIR-4100 spectrometer and absorption
bands are presented as wavenumber in cm−1. Electrospay
Quadrupole Time-of-Flight HRMS measurements were
performed with a MicroTOF-Q type QqTOF MS instrument
equipped with an ESI source from Bruker (Bruker Daltoniks,
Bremen, Germany). Elementary analysis was carried with a
Vario Micro V1.9.6 instrument.
Computational section: Mixed torsional/low mode con-
formational searches were carried out by means of the Macro-
model 9.9.223 software [25] using OPLS-2005 force field with
implicit solvent model for chloroform applying a 42 kJ/mol
energy window. Geometry reoptimizations (B3LYP/6-31G(d)
level in gas phase and B3LYP/TZVP level with PCM solvent
model for CHCl3) and TDDFT-ECD calculations were
performed with Gaussian 09 [26] using various functionals
(B3LYP, BH&HLYP, PBE0) and TZVP basis set for ECD
calculations. ECD spectra were generated as the sum of Gaus-
sians [27] with 2100, 2400 and 4200 cm−1 half-height width
(corresponding to ca. 19, 22 and 38 nm at 300 nm) using dipole-
velocity computed rotational strengths. Boltzmann distributions
were estimated from the ZPVE-corrected B3LYP/6-31G(d)
energies in the gas-phase calculations and from the B3LYP/
TZVP energies in the PCM ones. The MOLEKEL [28] soft-
ware package was used for visualization of the results.
Bioassay on neuroprotective activity: SH-SY5Y cells were
high passages from the American Type Culture Collection and
were maintained at 37 °C in a humidified atmosphere
containing 5% CO2. Cells were pretreated with compounds for
2 h and then suffered cell injury by treatment with 10 µM
Aβ25–35 or 100 µM H2O2 for another 24 h; to SH-SY5Y cells,
pretreated with compounds before exposed to OGD for 1 h, was
added 1 mg/mL glucose and 10% serum and cultured for
another 24 h under normal condition. SH-SY5Y cells cultured
with glucose under normal condition served as control. Cell
viability was evaluated by incubating cells with 0.5 mg/mL
3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide
(MTT) for 3 h under 5% CO2/95% air at 37 °C. After replace-
ment of the medium with 100 µL DMSO, absorbance was read
at 490 nm. Data were analyzed by one-way analysis of variance
(ANOVA) and expressed as means ± SD with P < 0.05 as
significance.
2-Phenyl-3,4-dihydro-1,4-benzoxazepin-5(2H)-one (rac-9):
To a stirred solution of racemic flavanone (rac-8, 10.00 g,
44.63 mmol) in TFA (55 mL), sodium azide (5.80 g,
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89.22 mmol) was added in two parts and the mixture was stirred
for 6 h. Cold diethyl ether (200 mL) was added to the reaction
mixture and stirring was continued for 1 h. The precipitated
white solid was filtered and refluxed in 180 mL water for 3 h.
After cooling to room temperature, it was refrigerated for 1 h,
the resultant precipitate was filtered and washed with cold
water. The product rac-9 was dried and isolated as white
powder (8.23 g, 77%) with mp 127–129 °C. 1H NMR (400
MHz, CDCl3) δ 3.54 (m, 3-Ha, 1H), 3.66 (m 3-Hb, 1H), 5.46
(dd, J = 9.7 and 3.6 Hz, 2-H, 1H), 7.07 (d, J = 8.4 Hz, 9-H, 1H),
7.19 (m, J = 7.6 Hz, 7-H, 1H), 7.28 (bs, NH, 1H), 7.36–7.44 (m,
Ph, 5H), 7.50 (m, J = 7.6 Hz, 8-H, 1H), 7.85 (dd, J = 8.0 and
1.6 Hz, 6-H, 1H); 13C NMR (100 MHz, CDCl3) δ 46.3 (C-3),
85.8 (C-2), 122.4 (C-9), 123.7 (C-7), 125.9 (C-5a), 126.3 (C-2’,
C-6’), 128.5 (C-4’), 128.7 (C-3’, C-5’), 130.9 (C-6), 133.3
(C-8), 139.0 (C-1’), 154.5 (C-9a), 170.9 (C-5); IR (KBr) ν:
1462, 1665, 2917, 3075, 3203, 3307 cm−1; HRMS–ESI (m/z):
[M + Na]+ calcd for C15H13NO2Na, 262.0844; found,
262.0839; Anal. calcd for C15H13NO2 (239.09): C, 75.30; H,
5.48; N, 5.85; found: C, 75.28; H, 5.49; N, 5.85.
2-Phenyl-2,3,4,5-tetrahydro-1,4-benzoxazepine (rac-10): To
a stirred solution of rac-9 (8.13 g, 33.98 mmol) in dry THF
(80 mL), 2.0 M lithium aluminium hydride solution in THF was
added dropwise (10 mL, 0.76 g, 20.03 mmol) and the mixture
was refluxed for 1.5 h. After cooling to room temperature, ethyl
acetate (5 mL), methanol (5 mL) and water (50 mL) were added
and the mixture was concentrated under reduced pressure. The
residue was extracted with dichloromethane (3 × 50 mL). The
combined organic layers were washed with water (20 mL),
dried over MgSO4, filtered and concentrated under reduced
pressure. The product rac-10 was isolated as yellow solid
(6.12 g, 80%) with mp 73–74 °C. 1H NMR (400 MHz, CDCl3)
δ 3.20 (dd, J = 14.4 and 10.0 Hz, 3-Hax, 1H), 3.37 (d, 3-Heq,
14.4 Hz, 1H), 3.96 (d, J = 14.8 Hz, 5-Ha, 1H), 4.12 (d, J = 14.8
Hz, 5-Hb, 1H), 4.66 (d, J = 10.0 Hz, 2-H, 1H), 7.04 (m, 7-H,
8-H, 2H), 7.17 (m, 6-H, 9-H, 2H), 7.31–7.43 (m, Ph, 5H); 13C
NMR (100 MHz, CDCl3) δ 52.5 (C-5), 58.9 (C-3), 86.4 (C-2),
121.6 (C-9), 123.6 (C-7), 125.8 (C-2’, C-6’), 127.7 (C-8), 128.4
(C-3’, C-5’), 129.0 (C-4’, C-6), 135.6 (C-5a), 140.5 (C-1’),
159.1 (C-9a); IR (KBr) ν: 1579, 2935, 3328 cm−1; HRMS–ESI
(m/z): [M + H]+ calcd for C15H16NO, 226.1232; found,
226.1235; Anal. calcd for C15H15NO (225.11): C, 79.97; H,
6.71; N, 6.22; found: C, 80.03; H, 6.76; N, 6.18.
5-Nitro-2-(2-phenyl-2,3-dihydro-1,4-benzoxazepin-4(5H)-
yl)benzaldehyde (rac-5): To the stirred solution of rac-10
(1.50 g, 6.66 mmol) in dry toluene (25 mL), anhydrous K2CO3
(1.85 g 13.39 mmol) and 2-fluoro-5-nitrobenzaldehyde (1.35 g,
7.98 mmol) were added and the mixture was refluxed for 8 h.
After cooling to room temperature, K2CO3 was filtered off and
toluene was removed under reduced pressure. The residue was
purified by column chromatography on silica gel (ethyl acetate/
hexane 4:1) to give rac-5 as yellow solid (1.77 g, 71%). Mp
152–156 °C; 1H NMR (400 MHz, CDCl3) δ 3.63 (dd, J = 10.8
and 13.6 Hz, 3-Hax, 1H), 4.04 (dd, J = 13.6 and 2.4 Hz, 3-Heq,
1H), 4.71 (d, J = 16.4 Hz, 5-Ha, 1H), 4.94 (d, J = 16.4 Hz, 5-Hb,
1H), 5.29 (dd, J = 10.8 and 2.4 Hz, 2-H, 1H), 7.03 (m, J = 9.6
Hz, 6-H, 9-H, 2H), 7.13 (m, 8-H, 1H), 7.26 (m, 6”-H, 7-H, 2H),
7.36–7.42 (m, Ph, 5H), 8.17 (dd, J = 9.2 Hz and 2.8 Hz, 5”-H,
1H), 8.61 (d, J = 2.8 Hz, 3”-H, 1H), 9.97 (s, CHO, 1H); 13C
NMR (100 MHz, CDCl3) δ 56.1 (C-5), 64.6 (C-3), 82.7 (C-2),
117.6 (C-6”), 121.0 (C-9), 123.8 (C-7), 124.3 (C-5a), 125.9
(C-2’, C-6’), 127.5 (C-2’’), 128.1 (C-4”), 128.7 (C-8, C-3”),
129.1 (C-3’, C-5’), 129.5 (C-5”), 129.8 (C-4’), 129.8 (C-6),
138.1 (C-1’), 156.8 (C-9a), 158.2 (C-1”), 188.3 (CHO); IR
(KBr) ν: 1382, 1500, 1681, 1734, 2921 cm−1; HRMS–ESI
(m/z): [M + Na]+ calcd for C22H18N2O4Na, 397.1164; found,
397.1158; Anal. calcd for C22H18N2O4 (374.12): C, 70.58; H,
4.85; N, 7.48; found: C, 70.59; H, 4.89; N, 7.45.
trans-1,3-Dimethyl-11'-nitro-2'-phenyl-1',2'-dihydro-
2H ,7b'H ,9 'H-spiro[pyrimidine-5,8'-quinolino[1,2-
d][1,4]benzoxazepine]-2,4,6(1H,3H)-trione (rac-trans-7a): To
a stirred solution of rac-5 (100 mg, 0.27 mmol) in chloroform
(5 mL), anhydrous MgSO4 (150 mg, 1.25 mmol) and 1,3-
dimethylbarbituric acid (60 mg, 0.38 mmol) were added and the
mixture was refluxed for 4 h. After cooling to room tempera-
ture, MgSO4 was filtered off and chloroform was removed
under reduced pressure. Water (10 mL) and dichloromethane
(20 mL) were added and the layers were separated. The aqueous
phase was extracted with dichloromethane (2 × 10 mL). The
combined organic layers were washed with concentrated
NaHCO3 solution, dried over MgSO4, filtered and concentrated
under reduced pressure. The oily product was triturated with
ether to afford rac-trans-7a as yellow solid (131 mg, 96%) with
mp 262–264 °C. 1H NMR (400 MHz, CDCl3) δ 2.91 (s, N-Me,
3H), 3.12 (d, J = 16.8 Hz, 9-Ha, 1H), 3.13 (s, N-Me, 3H), 3.87
(dd, J = 16.4 and 12.0 Hz, 3-Hax, 1H), 4.00 (d, J = 16.8 Hz,
9-Hb, 1H), 4.16 (dd, J = 12.0 and 3.2 Hz, 3-Heq, 1H), 4.81 (s,
15a-H, 1H), 5.13 (dd, J = 12.0 and 3.2 Hz, 2-H, 1H), 6.80 (d, J
= 7.6 Hz, 19-H, 1H), 6.85 (d, J = 9.2 Hz, 5-H, 1H), 7.10 (m,
16-H, Ph, 3H), 7.15 (m, 17-H, 1H), 7.30–7.38 (m, 18-H, Ph,
4H), 8.08 (dd, J = 9.2 and 2.4 Hz, 6-H, 1H), 8.13 (s, 8-H, 1H);
13C NMR (100 MHz, CDCl3) δ 28.7 (Me), 28.9 (Me), 34.7
(C-9), 47.3 (C-3) 51.9 (C-10), 71.5 (C-15a), 81.2 (C-2), 109.9
(C-19), 121.5 (C-15b), 123.8 (C-5), 124.7 (C-17), 124.8 (C-6),
125.5 (C-8a), 127.0 (C-2’ and C-6’), 128.8 (C-3’ and C-5’),
129.1 (C-8), 129.9 (C-18), 132.1 (C-16), 137.6 (C-7), 138.3
(C-1’), 147.6 (C-13), 150.1 (C-19a), 151.7 (C-4a), 167.1
(C-15), 168.9 (C-11); IR (KBr) ν: 749, 988, 1326, 1683, 2926
cm−1; HRMS–ESI (m/z): [M + Na]+ calcd for C28H24N4O6Na,
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535.1594; found, 535.1588; Anal. calcd for C28H24N4O6
(512.17): C, 65.65; H, 4.72; N, 10.93; found: C, 65.64; H, 4. 70;
N, 10.95. (2R,15aR)-7a: retention time (tR) 10.57 min
(Chiralpak IA, hexane/dichloromethane 70:30); HPLC-ECD
data in hexane/dichloromethane 70:30 as λmax (Φ): 378 (8.97),
368 sh (8.71), 314 (−12.73), 305 sh (−12.73), 284 (2.21), 272
(−1.54), 239 (16.42), 224 sh (11.27). (2S,15aS)-7a: retention
time (tR) 28.73 min (Chiralpak IA, hexane/dichloromethane
70:30); HPLC-ECD in hexane/dichloromethane 70:30 as λmax
(Φ): 381 sh (−4.83), 370 (−5.03), 314 (7.10), 305 sh (5.68), 286
(−1.24), 270 (0.78), 239 (−9.32), 221 (−11.60).
trans-2,2-Dimethyl-11'-nitro-2'-phenyl-1',2'-dihydro-
7 b ' H , 9 ' H - s p i r o [ 1 , 3 - d i o x a n e - 5 , 8 ' - q u i n o l i n o [ 1 , 2 -
d][1,4]benzoxazepine]-4,6-dione (rac-trans-7b): To the stirred
solution of rac-5 (100 mg, 0.27 mmol) in chloroform (5 mL),
anhydrous MgSO4 (150 mg, 1.25 mmol) and Meldrum’s acid
(54 mg, 0.31 mmol) were added and the mixture was refluxed
for 6 h. After cooling to room temperature, MgSO4 was filtered
off and chloroform was removed under reduced pressure. Water
(10 mL) and dichloromethane (20 mL) were added and the
layers were separated. The aqueous phase was extracted with
dichloromethane (2 ×10 mL). The combined organic layers
were washed with concentrated NaHCO3 solution, dried over
MgSO4, filtered and concentrated under reduced pressure. The
oily product was triturated with ether to afford rac-trans-7b as
yellow solid (30 mg, 22%) with mp 130–134 °C. 1H NMR (500
MHz, CDCl3) δ 1.06 (s, Me, 3H), 1.62 (s, Me, 3H), 3.19 (d, J =
16.5 Hz, 9-Ha, 1H), 3.90 (d, J = 16.5 Hz, 9-Hb, 1H), 3.95 (dd, J
= 16.5 and 11.5 Hz, 3-Hax, 1H), 4.16 (dd J = 16.5 Hz and 3.2
Hz, 3-Heq, 1H), 5.02 (s, 15a-H, 1H), 5.22 (dd, J = 11.5 Hz and
3.2 Hz, 2-H, 1H), 6.83 (d, J = 8.0 Hz, 19-H, 1H), 6.87 (d, J =
9.0 Hz, 5-H, 1H), 7.12 (m, 16-H, 1H), 7.22 (m, 17-H, 18-H,
2H), 7.27–7.35 (m, Ph, 5H), 8.09 (m, 8-H, 6-H, 2H); 13C NMR
(100 MHz, CDCl3) δ 26.9 (Me), 30.5 (Me), 35.7 (C-9), 47.2
(C-3), 50.0 (C-10), 70.7 (C-15a), 80.3 (C-2), 105.5 (C-13),
110.0 (C-19), 119.5 (C-8a), 125.1 (C-5), 125.2 (C-17), 125.6
(C-6), 126.7 (C-15b), 127.2 (C-2’, C-6’), 128.6 (C-3’, C-5’),
129.0 (C-8), 131.1 (C-4’), 131.4 (C-16), 137.3 (C-7), 138.1
(C-1’), 147.7 (C-19a), 152.2 (C-4a), 164.5 (C-15), 168.2
(C-11); IR (KBr) ν: 1197, 1322, 1507, 1737, 2925 cm−1;
HRMS–ESI (m/z): [M + Na]+ calcd for C28H24N2O7Na,
523.1481; found, 523.1475; Anal. calcd for C28H24N2O7
(500.16): C, 67.19; H, 4.83; N, 5.60; found: C, 67.17; H, 4.86;
N, 5.59. (2R,15aR)-7b: retention time (tR) 5.96 min (Chiralpak
IA, hexane/dichloromethane 70:30); HPLC-ECD data in
hexane/dichloromethane 70:30 as λmax (Φ): 379 sh (10.62), 368
(10.90), 312 (−9.79), 303 sh (−7.89), 279 (6.49), 261 sh
(−3.01), 251 (−3.30), 228 (15.44). (2S,15aS)-7b: retention time
(tR) 14.09 min (Chiralpak IA, hexane/dichloromethane 70:30);
HPLC-ECD data in hexane/dichloromethane 70:30 as λmax (Φ):
383 sh (−3.29), 371 (−3.71), 311 (3.16), 302 sh (2.75), 278
(−2.26), 260 sh (1.04), 249 (1.10), 227 (−5.51).
[5-Nitro-2-(2-phenyl-2,3-dihydro-1,4-benzoxazepin-4(5H)-
yl)benzylidene]propanedinitrile (7c): To the stirred solution
of rac-5 (100 mg, 0.27 mmol) in chloroform (5 mL), anhydrous
MgSO4 (150 mg, 1.25 mmol) and malononitrile (130 mg,
1.97 mmol) were added and the mixture was refluxed for 10 h.
After cooling to room temperature, MgSO4 was filtered off and
chloroform was removed under reduced pressure. Water
(10 mL) and dichloromethane (20 mL) were added and the
layers were separated. The aqueous phase was extracted with
dichloromethane (2 × 10 mL). The combined organic layers
were washed with concentrated NaHCO3 solution, dried over
MgSO4, filtered and concentrated under reduced pressure. The
oily product was triturated with ether to afford 7c as yellow
solid (91 mg, 81%) with mp 152–156 °C. 1H NMR (400 MHz,
CDCl3) δ 3.78 (m, 3-H, 2H), 4.50 (d, J = 15.6 Hz, 11-Ha, 1H),
4.58 (d, J = 15.6 Hz, 11-Hb, 1H), 5.06 (dd, J = 10.0 Hz and 2.4
Hz, 3-Heq, 1H), 7.15 (d, J = 8.0 Hz, 15-H, 1H), 7.16–7.26 (m,
12-H, 13-H, 14-H, 3H), 7.32 (m, 7-H, 1H), 7.41 (m, Ph, 5H),
7.75 (s, 16-H, 1H), 8.26 (dd, J = 9.2 Hz and 2.6 Hz, 7-H, 1H),
8.85 (d, J = 2.6 Hz, 9-H, 1H); 13C NMR (100 MHz, CDCl3) δ
59.4 (C-11), 63.2 (C-3), 82.9 (C-2), 84.3 (C-17), 111.8 (CN),
112.9 (CN), 119.2 (C-15), 121.5 (C-6), 121.9 (C-10), 124.5
(C-13), 125.9 (C-2’, C-6’, C-9), 128.4 (C-11a), 128.7 (C-7)
128.9 (C-3’, C-5’, C-14), 129.2 (C-4’), 129.9 (C-12), 138.2
(C-8), 141.2 (C-1’), 156.9 (C-16), 158.2 (C-15a), 158.5 (C-5)
IR (KBr) ν: 759, 1222, 1335, 1488, 2227, 2923 cm−1;
HRMS–ESI (m/z): [M+Na]+ calcd for C25H18N4O3Na,
445.1277; found, 445.1271; Anal. calcd for C28H18N4O3
(422.14): C, 71.08; H, 4.29; N, 13.26; found: C, 71.05; H, 4.30;
N, 13.25. First eluting enantiomer of 7c: retention time (tR)
21.41 min (Chiralpak IA, hexane/dichloromethane 80:20);
HPLC-ECD data in hexane/dichloromethane 80:20 as λmax (Φ):
348 (−4.21), 279 (3.84), 252 sh (1.62), 223 (2.04). Second
eluting enantiomer of 7c: retention time (tR) 21.41 min
(Chiralpak IA, hexane/dichloromethane 80:20); HPLC-ECD
data in hexane/dichloromethane 80:20 as λmax (Φ): 356 (3.97),
281 (−3.48), 250 sh (−1.32).
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